DIMA Biotechnology LTD is a research and development company of recombinant monoclonal antibody focusing on immune oncology products and services. DIMA’s proprietary B cell cloning and recombinant monoclonal antibody development platform, DimAb[TM], can efficiently generate high-quality monoclonal antibodies in high throughput. Their R&D team has many years of experience in monoclonal antibody development. They provide solutions for scientific research, clinical diagnosis and therapeutic R&D.
The mission for the company is to apply advanced biotechnology to provide new and effective solutions for cancer diagnosis and treatment.